Findings

What do systematic reviews say?

4,776 questions · 7,311 findings · 959 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1,498 · 20.5%GRADE not reported 303 · 4.1%Very low 1,839 · 25.2%Low 1,991 · 27.2%Moderate 1,277 · 17.5%High 403 · 5.5%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Intervention not reported

CI: Confidence interval · participants with normal or abnormal lipid profiles

The review found no eligible studies for this question.

1 finding from 1 review

Fluvastatin for lowering lipids 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Mean baseline values. · participants with normal or abnormal lipid profiles

1 finding from 1 review

Fluvastatin for lowering lipids 2018 · Cochrane Headline outcomes only
no estimate extracted
1 participants
GRADE not reported

Intervention not reported

WDAEs within 3‐12 weeks · participants with normal or abnormal lipid profiles

It is very uncertain whether the intervention changes WDAEs within 3‐12 weeks (very low certainty).

1 finding from 1 review

Fluvastatin for lowering lipids 2018 · Cochrane Headline outcomes only
RR 1.52 [0.94, 2.45]
16 studies · 3023 participants
Very low

Intervention not reported

LDL‐cholesterol fluvastatin 20 mg/day · participants with normal or abnormal lipid profiles

1 finding from 1 review

Fluvastatin for lowering lipids 2018 · Cochrane Headline outcomes only
no estimate extracted
55 studies · 9010 participants
High

Intervention not reported

LDL‐cholesterol fluvastatin 40 mg/day · participants with normal or abnormal lipid profiles

1 finding from 1 review

Fluvastatin for lowering lipids 2018 · Cochrane Headline outcomes only
no estimate extracted
57 studies · 3658 participants
High

Intervention not reported

LDL‐cholesterol fluvastatin 80 mg/day · participants with normal or abnormal lipid profiles

1 finding from 1 review

Fluvastatin for lowering lipids 2018 · Cochrane Headline outcomes only
no estimate extracted
32 studies · 4928 participants
High

Intervention not reported

CI: Confidence interval · participants with normal or abnormal lipid profiles

The review found no eligible studies for this question.

1 finding from 1 review

Fluvastatin for lowering lipids 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Mean baseline values. · participants with normal or abnormal lipid profiles

1 finding from 1 review

Fluvastatin for lowering lipids 2018 · Cochrane Headline outcomes only
no estimate extracted
1 participants
GRADE not reported

Intervention not reported

Total cholesterol fluvastatin 10 mg/day · participants with normal or abnormal lipid profiles

1 finding from 1 review

Fluvastatin for lowering lipids 2018 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 287 participants
High

Intervention not reported

Total cholesterol fluvastatin 20 mg/day · participants with normal or abnormal lipid profiles

1 finding from 1 review

Fluvastatin for lowering lipids 2018 · Cochrane Headline outcomes only
no estimate extracted
50 studies · 6309 participants
High

Intervention not reported

Total cholesterol fluvastatin 40 mg/day · participants with normal or abnormal lipid profiles

1 finding from 1 review

Fluvastatin for lowering lipids 2018 · Cochrane Headline outcomes only
no estimate extracted
55 studies · 2966 participants
High

Intramuscular corticosteroids vs oral corticosteroid

Relapse · patients with acute asthma

Intramuscular corticosteroids showed no clear difference in relapse compared with oral corticosteroids (low certainty).

3 findings from 1 review

Intramuscular versus oral corticosteroids to reduce relapses following discharge from the emergency department for… 2018 · Cochrane Headline outcomes only
RR 0.94 [0.72, 1.24]
9 studies · 804 participants
Low
Intramuscular versus oral corticosteroids to reduce relapses following discharge from the emergency department for… 2018 · Cochrane Headline outcomes only
RR 0.74 [0.51, 1.07]
7 studies · 742 participants
Moderate
Intramuscular versus oral corticosteroids to reduce relapses following discharge from the emergency department for… 2018 · Cochrane Headline outcomes only
RR 0.99 [0.74, 1.33]
5 studies · 556 participants
Low

Intramuscular corticosteroids vs oral corticosteroid

Adverse events · patients with acute asthma

Intramuscular corticosteroids showed no clear difference in adverse events compared with oral corticosteroids (low certainty).

1 finding from 1 review

Intramuscular versus oral corticosteroids to reduce relapses following discharge from the emergency department for… 2018 · Cochrane Headline outcomes only
RR 0.83 [0.64, 1.07]
5 studies · 404 participants
Low

Intramuscular corticosteroids vs oral corticosteroid

Persistence of symptoms · patients with acute asthma

Intramuscular corticosteroids showed no clear difference in symptom persistence compared with oral corticosteroids (low certainty).

1 finding from 1 review

Intramuscular versus oral corticosteroids to reduce relapses following discharge from the emergency department for… 2018 · Cochrane Headline outcomes only
RR 0.41 [0.14, 1.2]
3 studies · 80 participants
Low

Intramuscular corticosteroids vs oral corticosteroid

24‐hour beta agonist use · patients with acute asthma

Intramuscular corticosteroids showed no clear difference in 24‐hour beta agonist use compared with oral corticosteroids (low certainty).

1 finding from 1 review

Intramuscular versus oral corticosteroids to reduce relapses following discharge from the emergency department for… 2018 · Cochrane Headline outcomes only
RR 0.54 [0.21, 1.37]
2 studies · 48 participants
Low

Pembrolizumab vs chemotherapy alone

Time to death from any cause (here: overall mortality at 12‐month

Pembrolizumab probably leads to lower time to death from any cause (here: overall mortality at 12‐month compared with chemotherapy (moderate certainty).

1 finding from 1 review

Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression… 2018 · Cochrane Headline outcomes only
HR 0.73 [0.59, 0.9]
1 study · 542 participants
Moderate

Pembrolizumab vs chemotherapy alone

Quality of life (Change from baseline to week 15)

Pembrolizumab may leads to higher quality of life (Change from baseline to week 15) compared with chemotherapy (low certainty).

1 finding from 1 review

Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression… 2018 · Cochrane Headline outcomes only
MD 9.05 [4.61, 13.5]
1 study · 519 participants
Low

Pembrolizumab vs chemotherapy alone

Brain tumour response rates: complete response (CR) and partial response (PR) combinedNo. of participants: 847(6 RCTs)

Pembrolizumab probably leads to higher response rate (partial and complete response) compared with chemotherapy (moderate certainty).

1 finding from 1 review

Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression… 2018 · Cochrane Headline outcomes only
RR 1.85 [1.24, 2.77]
1 study · 542 participants
Moderate

Pembrolizumab vs chemotherapy alone

Treatment‐related mortality

Pembrolizumab showed no clear difference in treatment‐related mortality compared with chemotherapy (low certainty).

1 finding from 1 review

Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression… 2018 · Cochrane Headline outcomes only
RR 0.96 [0.24, 3.79]
1 study · 521 participants
Low

Pembrolizumab vs chemotherapy alone

Discontinuation of medication due to adverse events

Pembrolizumab showed no clear difference in discontinuation due to adverse event compared with chemotherapy (low certainty).

1 finding from 1 review

Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression… 2018 · Cochrane Headline outcomes only
RR 0.66 [0.39, 1.1]
1 study · 521 participants
Low